五脏俞募配穴揿针治疗缺血性中风后失眠的临床研究

注册号:

Registration number:

ITMCTR2025001235

最近更新日期:

Date of Last Refreshed on:

2025-06-21

注册时间:

Date of Registration:

2025-06-21

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

五脏俞募配穴揿针治疗缺血性中风后失眠的临床研究

Public title:

Press Needle Therapy at Paired Zang Organ Back-Shu and Front-Mu Points for Insomnia following Ischemic Stroke : A Clinical Study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

五脏俞募配穴揿针治疗缺血性中风后失眠的临床研究

Scientific title:

Press Needle Therapy at Paired Zang Organ Back-Shu and Front-Mu Points for Insomnia following Ischemic Stroke : A Clinical Study

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王倩倩

研究负责人:

杨文佳

Applicant:

Qianqian Wang

Study leader:

Wenjia Yang

申请注册联系人电话:

Applicant telephone:

15515675753

研究负责人电话:

Study leader's telephone:

15800690158

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1930334475@qq.com

研究负责人电子邮件:

Study leader's E-mail:

yangwenjia1030@163.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

上海市虹口区甘河路110号岳阳医院

研究负责人通讯地址:

上海市虹口区甘河路110号岳阳医院

Applicant address:

Yueyang Hospital No.110 Ganhe Rd Hongkou District Shanghai

Study leader's address:

Yueyang Hospital No.110 Ganhe Rd Hongkou District Shanghai

申请注册联系人邮政编码:

Applicant postcode:

200437

研究负责人邮政编码:

Study leader's postcode:

200437

申请人所在单位:

上海中医药大学附属岳阳中西医结合医院

Applicant's institution:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2025-125

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

上海中医药大学附属岳阳中西医结合医院伦理委员会

Name of the ethic committee:

Ethics Committee of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2025/5/15 0:00:00

伦理委员会联系人:

殷从全

Contact Name of the ethic committee:

Congquan Yin

伦理委员会联系地址:

上海市虹口区甘河路110号岳阳医院

Contact Address of the ethic committee:

Yueyang Hospital No.110 Ganhe Rd Hongkou District Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

021-65161782-8122

伦理委员会联系人邮箱:

Contact email of the ethic committee:

yyyyllwyh@163.com

研究实施负责(组长)单位:

上海中医药大学附属岳阳中西医结合医院

Primary sponsor:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine

研究实施负责(组长)单位地址:

上海市虹口区甘河路110号岳阳医院

Primary sponsor's address:

Yueyang Hospital No.110 Ganhe Rd Hongkou District Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

虹口区

Country:

China

Province:

Shanghai

City:

Hongkou District

单位(医院):

上海中医药大学附属岳阳中西医结合医院

具体地址:

上海市虹口区甘河路110号岳阳医院

Institution
hospital:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine

Address:

Yueyang Hospital No.110 Ganhe Rd Hongkou District Shanghai

经费或物资来源:

自筹

Source(s) of funding:

self-raised

研究疾病:

缺血性中风后失眠

研究疾病代码:

Target disease:

Insomnia following Ischemic Stroke

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

1. 观察五脏俞募配穴揿针疗法对缺血性中风后失眠的治疗效果,综合评估该疗法对中风后患者睡眠、抑郁焦虑、神经功能恢复、生活质量和认知的改善情况。 2.从神经递质调控的角度探讨五脏俞募配穴揿针疗法治疗缺血性中风后失眠的可能机制,分析揿针对患者血清神经递质水平的影响,探索治疗中风后失眠的中医现代化内涵,为缺血性中风后失眠这一特定人群的治疗提供新思路。

Objectives of Study:

1. To observe the therapeutic effect of five-shu and mu-acupoint catgut embedding therapy on post-ischemic stroke insomnia and comprehensively evaluate its improvements in sleep depression and anxiety neurological function recovery quality of life and cognition in post-stroke patients. 2. To explore the potential mechanisms of five-shu and mu-acupoint catgut embedding therapy in treating post-ischemic stroke insomnia from the perspective of neurotransmitter regulation analyze the impact of catgut embedding on patients' serum neurotransmitter levels and investigate the modernized connotation of traditional Chinese medicine in treating post-stroke insomnia thereby providing new insights for the treatment of this specific population.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)符合缺血性中风和失眠的中西医诊断标准(PSQI≥6) (2)缺血性中风首次发病者,病程≥2周,病情稳定 (3)年龄≥18且≤80岁,性别不限,语言障碍不影响交流,能独立填写问卷或回答问题。 (4)失眠继发于中风,缺血性中风患者发病前3月不曾有过失眠症状,不曾有长期服用安眠药物史。 (5)既往无揿针治疗经验患者 (6)患者或其家属签署知情同意书,自愿参加本研究。

Inclusion criteria

(1) Meets the diagnostic criteria for both traditional Chinese and Western medicine for ischemic stroke and insomnia (PSQI ≥ 6) (2) First-time ischemic stroke patients with a course of illness ≥ 2 weeks stable condition (3) Age ≥ 18 and ≤ 80 years gender language barriers do not affect communication able to independently complete the questionnaire or answer questions. (4) Insomnia is secondary to stroke ischemic stroke patients had no insomnia symptoms for 3 months prior to onset no history of long-term use of sleeping pills. (5) Patients with no prior experience of acupressure treatment The patient or their family member signs an informed consent form and voluntarily participates in this study.

排除标准:

(1)伴有严重感染,患有严重的心、肝、肾等重要脏器功能衰竭。 (2)有精神疾病病史或严重认知障碍,无法配合治疗和评估。 (3)酗酒和/或使用精神活性药物、药物滥用和依赖。 (4)妊娠期或哺乳期妇女。 (5)发病前3个月有过失眠情况或接受过失眠治疗者 (6)对揿针治疗有禁忌证或过敏史。 (7)正处于其他治疗性临床试验中者;

Exclusion criteria:

(1) Patients with severe infections or severe dysfunction of vital organs (e.g. heart liver kidney). (2) History of mental illness or severe cognitive impairment unable to cooperate with treatment and evaluation. (3) Alcohol abuse and/or use of psychoactive substances drug abuse or dependence. (4) Pregnant or lactating women. (5) History of insomnia or insomnia treatment within 3 months before stroke onset. (6) Contraindications or allergy to press-needle therapy. (7) Currently participating in other therapeutic clinical trials.

研究实施时间:

Study execute time:

From 2024-12-20

To      2026-04-01

征募观察对象时间:

Recruiting time:

From 2025-06-30

To      2025-11-30

干预措施:

Interventions:

组别:

对照组

样本量:

43

Group:

Control group

Sample size:

干预措施:

假揿针治疗

干预措施代码:

Intervention:

Sham press-needle therapy

Intervention code:

组别:

治疗组

样本量:

43

Group:

Intervention group

Sample size:

干预措施:

揿针治疗

干预措施代码:

Intervention:

press-needle therapy

Intervention code:

样本总量 Total sample size : 86

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

上海市

市(区县):

虹口区

Country:

China

Province:

Shanghai

City:

Hongkou District

单位(医院):

上海中医药大学附属岳阳中西医结合医院

单位级别:

三级甲等中西医结合医院,大学直属附属医院,国家中医临床研究基地

Institution/hospital:

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Shanghai University of Traditional Chinese Medicine

Level of the institution:

Class-III Grade-A Integrated Traditional Chinese and Western Medicine Hospital University-Affiliated Teaching Hospital National Clinical Research Center for Traditional Chinese Medicine

测量指标:

Outcomes:

指标中文名:

匹兹堡睡眠质量指数量表

指标类型:

主要指标

Outcome:

Pittsburgh Sleep Quality Index

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

美国国立卫生研究院卒中量表

指标类型:

次要指标

Outcome:

National Institutes of Health Stroke Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

汉密尔顿焦虑量表

指标类型:

次要指标

Outcome:

Hamilton Ansiety Sale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

汉密尔顿抑郁量表

指标类型:

次要指标

Outcome:

Hamilton Depression Sale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

腕动仪参数

指标类型:

次要指标

Outcome:

Actigraphy variables

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

卒中专用生存质量量表

指标类型:

次要指标

Outcome:

Stroke specific quality of life scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

蒙特利尔认知评估量表

指标类型:

次要指标

Outcome:

Montreal Cognitive Assessment

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清神经递质(血清5-羟基色胺、去甲肾上腺素、γ-氨基丁酸、谷氨酸和多巴胺)

指标类型:

次要指标

Outcome:

Serum Neurotransmitters (5-HT NE γ-GABA Glu DA)

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 18
Min age years
最大 80
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

使用SPSS26.0软件生成随机数列表,将86例中风后失眠患者按随机数列表随机分配到治疗组或对照组。记录每组对应的随机数。治疗方案随机分组,记录不同治疗方案对应的随机数。随机数字表和治疗方案打印出来后装入密封的不透明信封,将信封编号。受试者按签署知情同意书的顺序与信封上编号匹配,以此进行随机分组。受试者将密封的信封交给试验治疗人员进行干预。治疗组患者采用揿针治疗,对照组患者采用假揿针治疗。干预后,收集临床资料。在试验期间,产生随机数字表、纳入受试者、治疗干预、评估结果和分析数据过程分别由不同研究人员独立完成。只有治疗人员知道治疗方案的分配,患者和其他研究人员对这项分配均不知情。

Randomization Procedure (please state who generates the random number sequence and by what method):

SPSS26.0 software was used to generate a random number list and 86 patients with post-stroke insomnia were randomly assigned to the treatment group or the control group according to the random number list. Record the random number corresponding to each group. The treatment regimens were randomized and the randomization numbers corresponding to different treatment regimens were recorded. Print out the random number sheet and treatment plan and put it in a sealed opaque envelope numbering the envelope. Subjects were randomized by matching the number on the envelope in the order in which they signed the informed consent form. Subjects hand over the sealed envelope to the trial treatment staff for intervention. The patients in the treatment group were treated with acupuncture and the patients in the control group were treated with sham acupuncture. After the intervention clinical data were collected. During the trial the process of generating a random number table including subjects treating the intervention evaluating the results and analyzing the data was done independently by different researchers. Only the treatment staff is aware of the allocation of the treatment regimen and neither the patient nor the other researchers are aware of this allocation.

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

(1)病例报告表的填写与移交 研究者根据受试者的原始观察记录,及时、完整、正确、清晰地填写病例 报告表。每个入选病例必须完成病例报告,课题负责人确认所有病例报告表填 写正确完整,并与原始资料一致。完成的病例报告表有临床检查员审查后,交 数据管理员,进行数据录入与管理工作。 (2)无电子采集及管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

(1)Completion and Submission of Case Report Forms Researchers shall promptly completely accurately and clearly fill out the case report forms based on the original observation records of the subjects. Each enrolled case must complete a case report. The principal investigator shall confirm that all case report forms are filled out correctly and completely and are consistent with the original data. Completed case report forms shall be reviewed by clinical monitors and then submitted to the data manager for data entry and management. (2)no EDC

数据管理委员会:

Data Managemen Committee:

No

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统